Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (45)
September 8, 2003
-
Maurer's Healthcare Insight (44)
August 11, 2003
-
Maurer's Healthcare Insight (43)
July 14, 2003
-
Maurer's Healthcare Insight (42)
June 16, 2003
-
Maurer's Healthcare Insight (41)
May 19, 2003
-
Maurer's Healthcare Insight (40)
April 28, 2003
-
Maurer's Healthcare Insight (39)
April 14, 2003
-
Maurer's Healthcare Insight (Special)
March 24, 2003
-
Maurer's Healthcare Insight (Special)
March 17, 2003
-
Maurer's Healthcare Insight (38)
February 17, 2003
-
Maurer's Healthcare Insight (37)
January 20, 2003
-
Maurer's Healthcare Insight (36)
December 2, 2002
-
Maurer's Healthcare Insight (35)
November 11, 2002
-
Maurer's Healthcare Insight (33)
September 2, 2002
-
Maurer's Healthcare Insight (32)
August 5, 2002
-
Maurer's Healthcare Insight (31)
July 22, 2002
-
Maurer's Healthcare Insight (30)
July 1, 2002
-
Maurer's Healthcare Insight (29)
June 3, 2002
-
Maurer's Healthcare Insight (28)
May 20, 2002
-
Maurer's Healthcare Insight (27)
April 29, 2002
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…